In summary, our investigations of the mechanism of action of the novel CDK2/9 inhibitor fadraciclib in primary CLL cells confirmed that inhibition of CDK9 mediated transcription reduced Mcl-1 level and induced apoptosis in the CLL cells. The gene discussed is CDK2; the disease is B-cell chronic lymphocytic leukemia.